Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).

Autor: van den Berg K; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Schaap DP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Voogt ELK; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., de Groot JWB; Department of Medical Oncology, Isala Oncology Centre, Zwolle, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Melenhorst J; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands., de Wilt JHW; Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands., van Westreenen HL; Department of Surgery, Isala, Zwolle, the Netherlands., Aalbers AGJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van 't Veer M; Department of Research and Education, Catharina Hospital, Eindhoven, the Netherlands., Marijnen CAM; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands., Vincent J; Department of Medical Oncology, Elkerliek Hospital, Helmond, the Netherlands., Simkens LHJ; Department of Medical Oncology, Maxima Medical Centre, Veldhoven, the Netherlands., Peters NAJB; Department of Medical Oncology, St. Jans Hospital, Weert, the Netherlands., Berbée M; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands., Werter IM; Department of Medical Oncology, Rijnstate Hospital, Arnhem, the Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Peulen HMU; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands., van Lijnschoten IG; Department of Pathology, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, the Netherlands., Roef MJ; Department of Nuclear Medicine, Catharina Hospital, Eindhoven, the Netherlands., Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Bloemen JG; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Willems JMWE; Department of Medical Oncology, Anna Hospital, Geldrop, the Netherlands., Creemers GJM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Nederend J; Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands., Rutten HJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands. pim.burger@catharinaziekenhuis.nl.

Publikováno v: BMC cancer [BMC Cancer] 2022 Sep 06; Vol. 22 (1), pp. 957. Date of Electronic Publication: 2022 Sep 06.